Manufacturing Multispecific mAbs: Why Complexity Demands the Right CDMO Partner

Multispecific monoclonal antibodies (mAbs) — including bispecific and trispecific formats — represent one of the most promising frontiers in biologics development. By engaging multiple targets simultaneously, these molecules unlock mechanisms of action that traditional mAbs cannot achieve, from T-cell redirection in oncology to dual-pathway modulation in autoimmune disease.

But the therapeutic promise of multispecific mAbs comes with a manufacturing reality that many biotech companies underestimate: these molecules are significantly harder to produce, purify, and characterize than conventional antibodies. The structural complexity that makes them therapeutically valuable also introduces manufacturing challenges that can delay timelines, increase costs, and jeopardize regulatory submissions.

For biotech manufacturing and CMC leaders evaluating CDMO partners, the question is not whether multispecific mAbs are worth pursuing — the clinical pipeline has already answered that. The question is whether your manufacturing partner has the expertise, infrastructure, and process discipline to deliver these complex molecules at scale.

The Manufacturing Challenge: Why Multispecific mAbs Are Different

Traditional monoclonal antibody manufacturing relies on well-established platform processes. A conventional IgG consists of two identical heavy chains and two identical light chains, and decades of industry experience have optimized cell line development, upstream processing, and purification for this symmetric architecture.

Multispecific mAbs break this symmetry. A bispecific antibody, for example, may require two different heavy chains and two different light chains to assemble correctly — creating the potential for multiple mispaired species that must be separated from the desired product. Trispecific formats add further complexity.

The manufacturing implications are significant across every stage of development:

Cell Line Development: Traditional cell line development (CLD) processes struggle to keep pace with the structural complexity of multispecific molecules. Expression of multiple polypeptide chains requires careful vector design, selection strategies that favor correct assembly, and screening methods that can distinguish correctly paired molecules from mispaired variants. Lower expression levels and the presence of aggregates, fragments, and chain mispairing are common challenges.

Upstream Processing: Multispecific formats often exhibit lower expression levels compared to traditional mAbs. Cell culture conditions, media optimization, and process parameters must be tailored to maximize yield of the correctly assembled molecule while minimizing product-related impurities.

Downstream Purification: Incorrectly paired variants generated upstream place an additional burden on purification processes. Many mispaired species exhibit biophysical properties — such as molecular weight and isoelectric point — that are difficult to distinguish from the desired product using standard chromatography methods. This often requires development of bespoke purification strategies, including multimodal chromatography approaches.

Analytical Characterization: Establishing analytical methods of sufficient sensitivity to distinguish between correctly and incorrectly assembled antibody products is critical. Liquid chromatography/mass spectrometry (LC/MS) methods, including deglycosylated intact MS, are often required to identify mispaired variants. Bioassays must accurately reflect the dual or multi-mechanism activity of the molecule.

Stability and Formulation: Multispecific formats can introduce unique stability challenges, including increased aggregation propensity and altered colloidal stability. Formulation development must account for these properties to ensure shelf-life and administration requirements are met.

What to Look for in a Multispecific mAb CDMO Partner

Given these challenges, selecting the right mAb CDMO partner is a strategic decision that can determine whether a multispecific program succeeds or stalls. Key capabilities to evaluate include:

Demonstrated Experience with Complex Formats: Look for a CDMO with explicit experience in bispecific and trispecific antibody manufacturing — not just traditional mAbs. The process development expertise required for multispecific formats is distinct and cannot be assumed from conventional biologics experience alone.

Flexible Manufacturing Infrastructure: Multispecific programs often require flexibility in bioreactor scale, suite configuration, and equipment options. A CDMO with both single-use bioreactors (SUBs) and stainless steel equipment options can adapt to program-specific requirements.

Integrated Analytical Capabilities: Robust analytical services — including HPLC, electrophoresis, mass spectrometry, and host cell protein analysis — are essential for characterizing multispecific molecules and identifying product-related impurities.

Regulatory Expertise: Multispecific mAbs often face heightened regulatory scrutiny due to their complexity. A CDMO with deep regulatory filing expertise and global marketing approval experience can help navigate CMC requirements and support first-cycle approval.

End-to-End Supply Chain Integration: The ability to support the extended supply chain — from drug substance to drug product, including fill-finish and packaging — reduces handoff risk and ensures quality consistency.

AbbVie Contract Manufacturing: A Proven Partner for Complex Biologics

AbbVie Contract Manufacturing brings over 35 years of biologics manufacturing experience to multispecific mAb programs. As an embedded CMO within a global biopharmaceutical company, AbbVie CMO offers the technical depth of a large pharma organization combined with the client focus of a dedicated contract manufacturer.

Mammalian Modality Expertise: AbbVie's biologics capabilities explicitly include monoclonal antibodies, multispecific mAbs, fusion proteins, bispecific and trispecific antibodies, and antibody drug conjugates (ADCs). This breadth of experience means AbbVie CMO understands the unique manufacturing requirements of complex antibody formats.

Scalable Manufacturing Infrastructure: AbbVie offers pre-clinical to commercial mammalian manufacturing with bioreactor capacities from 2,000L to 12,000L. Capabilities include 2,000L single-use bioreactors (SUBs) and 3,000L, 6,000L, and 12,000L stainless steel equipment options in various suite configurations across facilities in the US, Europe, and Singapore.

Comprehensive Development Services: AbbVie CMO provides cell line development (MCB/WCB), upstream/downstream process development, optimization and scale-up, stability studies and analytical characterization, cGMP manufacturing, and regulatory guidance including filing and global marketing approval support.

Integrated End-to-End Supply Chain: AbbVie is positioned to support the extended supply chain from drug substance to drug product, including all elements of ADC manufacturing within a single quality and operational network.

Proven Track Record: AbbVie CMO consistently ranks among the top monoclonal antibody production CMOs based on client satisfaction, performance, and product delivery.

Conclusion: Complexity Requires Capability

Multispecific mAbs represent a significant opportunity for biotech companies — but only if manufacturing challenges can be overcome. The structural complexity that enables novel mechanisms of action also demands manufacturing partners with deep expertise in cell line development, process optimization, purification, and analytical characterization.

For CMC leaders evaluating CDMO partners, the decision should be grounded in demonstrated capability with complex antibody formats, not assumptions based on traditional mAb experience.

The right partner can accelerate timelines, reduce risk, and support successful regulatory submissions.

AbbVie Contract Manufacturing offers the expertise, infrastructure, and integrated quality systems to help biotech companies navigate the complexity of multispecific mAb manufacturing — from early development through commercial supply.